ArticleCureus2026
Pre-exposure Prophylaxis Outcomes in High-Risk Individuals in Saudi Arabia: A 48-Week Observational Cohort Study.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Human immunodeficiency virus (HIV) continues to pose a substantial global health challenge, with an increasing burden observed in the Middle East and North Africa (MENA) region despite advancements in preventive measures. Pre-exposure prophylaxis (PrEP) has demonstrated high efficacy globally; however, data from real-world settings within the MENA region, particularly Saudi Arabia, remain limited. This study aims to evaluate the effectiveness, safety, adherence, and implementation outcomes of PrEP among a high-risk population. Methods This prospective, single-center, observational cohort study was conducted at Dammam Medical Complex, Saudi Arabia. A total of 50 HIV-negative adults at high risk of HIV infection were enrolled and followed for 48 weeks. Participants received tenofovir alafenamide/emtricitabine (TAF/FTC) as either daily or on-demand PrEP. The primary outcome was HIV incidence per 100 person-years. Secondary outcomes included retention in care, visit adherence, safety (renal, hepatic, and bone), adherence levels, sexually transmitted infection (STI) incidence, and implementation challenges. Descriptive statistics and paired analyses were performed. Results Human immunodeficiency virus seroconversions were not observed over 48 weeks, yielding an incidence of 0 per 100 person-years (95% CI: 0.0-0.071). Retention in care was high (94%), with similar visit adherence (94%). Adherence exceeded 90% in 92% of participants, with 100% adherence among daily PrEP users. Adverse events were infrequent (6%) and mild, with no discontinuations due to safety concerns. Small but statistically significant changes in renal function and bone mineral density were observed, without clinical relevance. STI incidence was 35.4 per 100 person-years, with 30% of participants acquiring at least one STI. High-risk behaviors persisted, including condomless sex (68%). Conclusion Tenofovir alafenamide/emtricitabine-based PrEP demonstrated excellent effectiveness, safety, and adherence in a real-world setting in Saudi Arabia. Despite these favorable outcomes, high STI incidence and ongoing risk behaviors highlight the need for integrated prevention strategies. These findings support the expansion of PrEP programs in MENA while emphasizing the importance of comprehensive sexual health interventions and larger multicenter studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.